Leuprolide (5-9)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 462761

CAS#: 129244-90-2

Description: Leuprolide (5-9) is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, and early puberty. It is given by injection into a muscle or under the skin.

Chemical Structure

img
Leuprolide (5-9)
CAS# 129244-90-2
Instruction

Theoretical Analysis

MedKoo Cat#: 462761
Name: Leuprolide (5-9)
CAS#: 129244-90-2
Chemical Formula: C34H57N9O6
Exact Mass: 687.44
Molecular Weight: 687.887
Elemental Analysis: C, 59.37; H, 8.35; N, 18.33; O, 13.95

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: 5-9-Leuprolide; Leuprolide (m1); Leuprolide (metabolite 1);

IUPAC/Chemical Name: (S)-1-(L-tyrosyl-D-leucyl-L-leucyl-L-arginyl)-N-ethylpyrrolidine-2-carboxamide

InChi Key: IFXGEYGBHGKGSQ-KLMIGJKJSA-N

InChi Code: InChI=1S/C34H57N9O6/c1-6-38-32(48)28-10-8-16-43(28)33(49)25(9-7-15-39-34(36)37)40-30(46)27(18-21(4)5)42-31(47)26(17-20(2)3)41-29(45)24(35)19-22-11-13-23(44)14-12-22/h11-14,20-21,24-28,44H,6-10,15-19,35H2,1-5H3,(H,38,48)(H,40,46)(H,41,45)(H,42,47)(H4,36,37,39)/t24-,25-,26+,27-,28-/m0/s1

SMILES Code: CCNC([C@@H]1CCCN1C([C@@H](NC([C@@H](NC([C@H](NC([C@H](Cc2ccc(O)cc2)N)=O)CC(C)C)=O)CC(C)C)=O)CCCNC(N)=N)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 687.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Saggar V, Wu S, Dickler MN, Lacouture ME. Alopecia with endocrine therapies in patients with cancer. Oncologist. 2013;18(10):1126-34. doi: 10.1634/theoncologist.2013-0193. Epub 2013 Sep 13. PMID: 24037977; PMCID: PMC3805155.

2: Ito Y, Ochii Y, Fukushima K, Sugioka N, Takada K. Three-layered microcapsules as a long-term sustained release injection preparation. Int J Pharm. 2010 Jan 15;384(1-2):53-9. doi: 10.1016/j.ijpharm.2009.09.032. Epub 2009 Sep 25. PMID: 19782737.

3: Hsieh YY, Chang CC, Tsai HD. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan J Obstet Gynecol. 2008 Mar;47(1):66-74. doi: 10.1016/S1028-4559(08)60057-1. PMID: 18400585.

4: Esinler I. Microdose flare-up vs. flexible-multidose GnRH antagonist protocols for poor responder patients who underwent ICSI. Clin Exp Obstet Gynecol. 2014;41(4):384-8. PMID: 25134281.

5: Gatti M, Poluzzi E, De Ponti F, Raschi E. Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis. Drug Saf. 2020 Aug 3. doi: 10.1007/s40264-020-00975-8. Epub ahead of print. PMID: 32748236.

6: Papadimitriou DT, Dermitzaki E, Papagianni M, Papaioannou G, Papaevangelou V, Papadimitriou A. Anastrozole plus leuprorelin in early maturing girls with compromised growth: the "GAIL" study. J Endocrinol Invest. 2016 Apr;39(4):439-46. doi: 10.1007/s40618-015-0399-z. Epub 2015 Oct 27. PMID: 26507391; PMCID: PMC4799269.

7: Nam HK, Kim HR, Rhie YJ, Lee KH. Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment. J Korean Med Sci. 2017 Mar;32(3):475-479. doi: 10.3346/jkms.2017.32.3.475. PMID: 28145651; PMCID: PMC5290107.

8: Chang JI, Bucci J. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report. J Med Case Rep. 2016 Nov 11;10(1):323. doi: 10.1186/s13256-016-1110-5. PMID: 27836000; PMCID: PMC5106809.

9: Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8. doi: 10.1210/jc.2005-2507. Epub 2006 Jan 24. PMID: 16434464.

10: Elassar A, Nulsen J, Engmann L, Benadiva C. Estradiol and Antagonist Pretreatment Prior to Microdose Leuprolide in in Vitro Fertilization. Does It Improve IVF Outcomes in Poor Responders as Compared to Oral Contraceptive Pill? J Reprod Med. 2015 May-Jun;60(5-6):199-204. PMID: 26126304.

11: Yamasaki H, Douchi T, Yamamoto S, Oki T, Kuwahata R, Nagata Y. Body fat distribution and body composition during GnRH agonist therapy. Obstet Gynecol. 2001 Mar;97(3):338-42. doi: 10.1016/s0029-7844(00)01181-9. PMID: 11239633.

12: Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Jul;82(7):2108-16. doi: 10.1210/jcem.82.7.4069. PMID: 9215280.

13: Tung YC, Lee JS, Tsai WY, Hsiao PH. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty. J Formos Med Assoc. 2007 Oct;106(10):826-31. doi: 10.1016/S0929-6646(08)60047-9. PMID: 17964961.

14: Sakata M, Terakawa N, Mizutani T, Tanizawa O, Matsumoto K, Terada N, Sudo K. Effects of danazol, gonadotropin-releasing hormone agonist, and a combination of danazol and gonadotropin-releasing hormone agonist on experimental endometriosis. Am J Obstet Gynecol. 1990 Nov;163(5 Pt 1):1679-84. doi: 10.1016/0002-9378(90)90650-v. PMID: 2122726.

15: Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440. PMID: 18348297; PMCID: PMC2562782.

16: Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, Saenger P, Shulman D, Silverman L, Flood L, Gray W, Tierney D. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007 May;92(5):1697-704. doi: 10.1210/jc.2006-2479. Epub 2007 Feb 27. PMID: 17327379.

17: Lavorato HL, Oliveira JB, Petersen CG, Vagnini L, Mauri AL, Cavagna M, Baruffi RL, Franco JG Jr. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis in granulosa cells. Eur J Obstet Gynecol Reprod Biol. 2012 Nov;165(1):61-5. doi: 10.1016/j.ejogrb.2012.07.014. Epub 2012 Aug 9. PMID: 22884794.

18: Chiumello G, Brambilla P, Guarneri MP, Russo G, Manzoni P, Sgaramella P. Precocious puberty and body composition: effects of GnRH analog treatment. J Pediatr Endocrinol Metab. 2000 Jul;13 Suppl 1:791-4. doi: 10.1515/jpem.2000.13.s1.791. PMID: 10969923.

19: Douchi T, Kuwahata R, Yamasaki H, Yamamoto S, Oki T, Nakae M, Nagata Y. Inverse relationship between the changes in trunk lean and fat mass during gonadotropin-releasing hormone agonist therapy. Maturitas. 2002 May 20;42(1):31-5. doi: 10.1016/s0378-5122(02)00004-x. PMID: 12020977.

20: Thompson DL, Horton N, Rittmaster RS. Androsterone glucuronide is a marker of adrenal hyperandrogenism in hirsute women. Clin Endocrinol (Oxf). 1990 Mar;32(3):283-92. doi: 10.1111/j.1365-2265.1990.tb00868.x. PMID: 2160872.